Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$229 Mln
Revenue (TTM)
$36 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.4 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1
Industry P/E
--
EV/EBITDA
-0.4
Div. Yield
0 %
Debt to Equity
0.2
Book Value
$3.1
EPS
$-1.3
Face value
--
Shares outstanding
97,578,175
CFO
$-328.36 Mln
EBITDA
$-444.92 Mln
Net Profit
$-461.17 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
C4 Therapeutics Inc (CCCC)
| 47.6 | 4.4 | 47.6 | 96.5 | -3.5 | -40.8 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
C4 Therapeutics Inc (CCCC)
| -46.9 | -36.0 | -4.2 | -81.7 | -2.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
C4 Therapeutics Inc (CCCC)
|
2.8 | 229.3 | 36.0 | -105.0 | -306.6 | -44.4 | -- | 1.0 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or... IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Address: 490 Arsenal Way, Watertown, MA, United States, 02472 Read more
CEO, President & Director
Mr. Andrew J. Hirsch M.B.A.
CEO, President & Director
Mr. Andrew J. Hirsch M.B.A.
Headquarters
Watertown, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of C4 Therapeutics Inc (CCCC) is $2.82 (NASDAQ) as of 02-Apr-2026 18:13 EDT. C4 Therapeutics Inc (CCCC) has given a return of -3.52% in the last 3 years.
Since, TTM earnings of C4 Therapeutics Inc (CCCC) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-1.51
|
0.62
|
|
2024
|
-2.41
|
1.18
|
|
2023
|
-2.18
|
1.18
|
|
2022
|
-2.25
|
1.00
|
|
2021
|
-18.61
|
4.01
|
The 52-week high and low of C4 Therapeutics Inc (CCCC) are Rs 3.82 and Rs 1.09 as of 05-Apr-2026.
C4 Therapeutics Inc (CCCC) has a market capitalisation of $ 229 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in C4 Therapeutics Inc (CCCC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.12
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.